"POEMS Syndrome" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A multisystemic disorder characterized by a sensorimotor polyneuropathy (POLYNEUROPATHIES), organomegaly, endocrinopathy, monoclonal gammopathy, and pigmentary skin changes. Other clinical features which may be present include EDEMA; CACHEXIA; microangiopathic glomerulopathy; pulmonary hypertension (HYPERTENSION, PULMONARY); cutaneous necrosis; THROMBOCYTOSIS; and POLYCYTHEMIA. This disorder is frequently associated with osteosclerotic myeloma. (From Adams et al., Principles of Neurology, 6th ed, p1335; Rev Med Interne 1997;18(7):553-62)
| Descriptor ID |
D016878
|
| MeSH Number(s) |
C10.668.829.800.700 C15.378.147.780.750 C16.131.077.703 C20.683.780.750
|
| Concept/Terms |
POEMS Syndrome- POEMS Syndrome
- Syndrome, POEMS
- Takatsuki's Syndrome
- Syndrome, Takatsuki's
- Takatsuki Syndrome
- Polyneuropathy Organomegaly
- Organomegalies, Polyneuropathy
- Organomegaly, Polyneuropathy
- Polyneuropathy Organomegalies
- Crow-Fukase Syndrome
- Crow Fukase Syndrome
- Syndrome, Crow-Fukase
- Polyneuropathy, Organomegaly, Endocrinopathy, M Protein, and Skin Changes Syndrome
|
Below are MeSH descriptors whose meaning is more general than "POEMS Syndrome".
Below are MeSH descriptors whose meaning is more specific than "POEMS Syndrome".
This graph shows the total number of publications written about "POEMS Syndrome" by people in this website by year, and whether "POEMS Syndrome" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "POEMS Syndrome" by people in Profiles.
-
Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma. Blood Adv. 2022 07 12; 6(13):3991-3995.